Methyldopa kinetics before and after ingestion of methyldopa for eight weeks

Area of Science:

• Pharmacokinetics
• Drug Metabolism and Transporter Studies

Background:

• Methyldopa is a widely used antihypertensive medication.
• Previous studies suggested methyldopa might induce its own absorption and renal clearance.
• Understanding these pharmacokinetic changes is crucial for optimizing therapeutic efficacy.

Purpose of the Study:

• To assess changes in methyldopa absorption and renal clearance after eight weeks of daily oral administration.
• To investigate the relationship between initial pharmacokinetic parameters and their subsequent changes.
• To reconcile conflicting findings regarding methyldopa's auto-induction potential.

Main Methods:

• Intravenous (IV) and oral (PO) administration of methyldopa.
• Measurement of methyldopa and its metabolites in urine and plasma.
• Assessment of absorption and renal clearance before and after an eight-week treatment period.
• Statistical analysis of the relationship between initial and changed pharmacokinetic values.

Main Results:

• No significant increase in estimated methyldopa absorption (8.4%) or renal clearance (PO 13.9%, IV 2.33%) was observed after eight weeks.
• Initial absorption and renal clearance values were higher than reported in previous studies.
• An inverse relationship was found between initial absorption/renal clearance and the change in these parameters.
• Individuals with lower initial absorption and clearance showed the greatest increases, consistent with transporter induction.

Conclusions:

• This study did not confirm previous findings of methyldopa-induced increases in absorption and renal clearance.
• Prior upregulation of transporter function may explain the lack of observed induction.
• Methyldopa appears to induce drug transporters, with greater effects seen in individuals with initially lower pharmacokinetic parameters.